Warner-Lambert Sudafed sales up 7% to $43 mil.; Listerine mouthwash gains 6%.
This article was originally published in The Tan Sheet
Executive Summary
WARNER-LAMBERT SUDAFED SALES GAIN 7% IN THIRD QUARTER to $43 mil., the firm reported Oct. 22. The cold medication, one of Warner-Lambert's best performing consumer health care products in the quarter, recently was extended with Cold & Sinus gelcaps and Children's Chewable tablets. Listerine antiseptic mouthwash grew 6% to $98 mil. in the period, and Nix head lice medication increased 60% to $21 mil. Nix benefitted from an increase in the total head lice treatment category and from wider U.S. distribution